5.44MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Purple Biotech Ltd
Currency: USD Updated: 2026-02-06 Key Insights
Purple Biotech Ltd's fundamentals are relatively weak, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 201 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 34.00.In the medium term, the stock price is expected to trend down.The company has shown weak stock market performance over the past month, in line with its weak fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Purple Biotech Ltd's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Purple Biotech Ltd Highlights
StrengthsRisks
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-02-06 The current financial score of Purple Biotech Ltd is 5.96, ranking 308 out of 392 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low.
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Key Metrics
Total revenue
Operating profit
Total assets
SG&A
Relevant data have not been disclosed by the company yet.
Key Metrics
Cash flow from operating activities
Income after tax
Relevant data have not been disclosed by the company yet.
Key Metrics
Cash flow from operating activities
Total revenue
Relevant data have not been disclosed by the company yet.
Key Metrics
Relevant data have not been disclosed by the company yet.
Purple Biotech Ltd's Company Valuation
Currency: USD Updated: 2026-02-06The current valuation score of Purple Biotech Ltd is 7.34, ranking 133 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -1.93, which is -42.75% below the recent high of -1.10 and -20438.40% above the recent low of -396.29.
Valuation Dimensions
Industry Ranking 201/392
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-02-06The current earnings forecast score of Purple Biotech Ltd is 8.00, ranking 164 out of 392 in the Biotechnology & Medical Research industry. The average price target is 34.00, with a high of 34.00 and a low of 34.00.
Support & Resistance
Relevant data have not been disclosed by the company yet.
Strong Buy
Buy
Hold
Sell
Strong Sell
CRISPR Therapeutics AG
CRSP
29
Intellia Therapeutics Inc
NTLA
24
Financial Forecasting
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-02-06The current price momentum score of Purple Biotech Ltd is 2.43, ranking 376 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 0.70 and the support level at 0.52, making it suitable for range-bound swing trading.
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Institutional Confidence
Currency: USD Updated: 2026-02-06Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Lincoln Alternative Strategies LLC
BNP Paribas Securities Corp. North America
UBS Financial Services, Inc.
Rhumbline Advisers Ltd. Partnership
Risk Assessment
Currency: USD Updated: 2026-02-06The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. No risk assessment score is currently available for Purple Biotech Ltd. The Biotechnology & Medical Research industry's average is 3.38. The company's beta value is 0.61. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.
Beta vs S&P 500 index
0.61
240-Day Maximum Drawdown
+81.66%
240-Day Volatility
+129.36%
Volatility
Downside Risk-Adjusted Return
Maximum Daily Upside Volatility
Maximum Daily Downside Volatility
Biotechnology & Medical Research
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ionis Pharmaceuticals Inc
IONS
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BCRX
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
